KR102823187B1 - 푸린 억제제 - Google Patents

푸린 억제제 Download PDF

Info

Publication number
KR102823187B1
KR102823187B1 KR1020207035245A KR20207035245A KR102823187B1 KR 102823187 B1 KR102823187 B1 KR 102823187B1 KR 1020207035245 A KR1020207035245 A KR 1020207035245A KR 20207035245 A KR20207035245 A KR 20207035245A KR 102823187 B1 KR102823187 B1 KR 102823187B1
Authority
KR
South Korea
Prior art keywords
methyl
pyridin
oxy
dichlorophenyl
piperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207035245A
Other languages
English (en)
Korean (ko)
Other versions
KR20210021298A (ko
Inventor
제프리 마이클 액스텐
무이 처웅
마이클 피. 드마르티노
후이핑 아미 구안
옌 후
애런 베인 밀러
동후이 친
청더 우
즈리우 장
샤오쥐엔 린
Original Assignee
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 filed Critical 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드
Publication of KR20210021298A publication Critical patent/KR20210021298A/ko
Application granted granted Critical
Publication of KR102823187B1 publication Critical patent/KR102823187B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
KR1020207035245A 2018-05-11 2019-05-10 푸린 억제제 Active KR102823187B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862670050P 2018-05-11 2018-05-11
US62/670,050 2018-05-11
PCT/EP2019/062098 WO2019215341A1 (en) 2018-05-11 2019-05-10 Furin inhibitors

Publications (2)

Publication Number Publication Date
KR20210021298A KR20210021298A (ko) 2021-02-25
KR102823187B1 true KR102823187B1 (ko) 2025-06-20

Family

ID=66597541

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207035245A Active KR102823187B1 (ko) 2018-05-11 2019-05-10 푸린 억제제

Country Status (12)

Country Link
US (1) US11773078B2 (cg-RX-API-DMAC7.html)
EP (1) EP3790871B1 (cg-RX-API-DMAC7.html)
JP (1) JP7350061B2 (cg-RX-API-DMAC7.html)
KR (1) KR102823187B1 (cg-RX-API-DMAC7.html)
CN (1) CN112384509B (cg-RX-API-DMAC7.html)
AU (1) AU2019267166C1 (cg-RX-API-DMAC7.html)
BR (1) BR112020022961A2 (cg-RX-API-DMAC7.html)
CA (1) CA3099863A1 (cg-RX-API-DMAC7.html)
IL (2) IL302997B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020012034A (cg-RX-API-DMAC7.html)
SG (1) SG11202010914YA (cg-RX-API-DMAC7.html)
WO (1) WO2019215341A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202010914YA (en) 2018-05-11 2020-12-30 Glaxosmithkline Ip Dev Ltd Furin inhibitors
WO2021097002A1 (en) * 2019-11-12 2021-05-20 Bp Asset V, Inc. Use of pyridyloxypyrimidines for treating infectious diseases
WO2021097008A1 (en) * 2019-11-12 2021-05-20 Bp Asset V, Inc. Use of pyridyloxypyridines for treating infectious diseases
JP2023503852A (ja) * 2019-11-12 2023-02-01 ビーピー アセット ヴイ,インコーポレーテッド 感染症を処置するための低分子フーリン阻害剤
JP2023521032A (ja) * 2020-04-02 2023-05-23 ビーピー アセット ヴイ,インコーポレーテッド コロナウイルス感染症を処置するためのフーリンインヒビター
FR3110345B1 (fr) 2020-05-21 2024-03-29 Agence Francaise Pour Le Dev D’Al Ula Hydrolysat de protéines du tourteau des graines de Moringa peregrina pour son application en tant que médicament, son procédé d’obtention et compositions pharmaceutiques, dermatologiques et cosmétiques.
CN117222410A (zh) * 2021-02-03 2023-12-12 Bp资产V股份有限公司 用于吸入的弗林蛋白酶抑制剂的制剂
CN114853640A (zh) * 2022-05-12 2022-08-05 马鞍山昂扬新材料科技有限公司 2-溴乙基磺酸钠的制备方法
EP4594312A1 (en) * 2022-09-29 2025-08-06 BP Asset V, Inc. 4-((2-(3,5-dichlorophenyl)-6-((pyrimidin-5-yl)oxy)pyridin-4-yl)methyl)piperazine derivatives as furin inhibitors and uses thereof
DE102023126563A1 (de) * 2023-09-28 2025-04-03 Philipps-Universität Marburg, Körperschaft des öffentlichen Rechts Hemmstoffe der Proproteinkonvertase Furin, Verfahren zu deren Herstellung und Verwendung
CN119119096B (zh) * 2024-09-09 2025-09-16 郑州药领医药科技有限公司 一种4-((4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)甲基)哌啶-1-甲酸叔丁酯的合成方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007046781A1 (en) 2004-07-23 2007-04-26 Smith, Judith Furin inhibitors
WO2013138665A1 (en) 2012-03-16 2013-09-19 Sanford-Burnham Medical Research Institute Inhibitors of furin and other pro-protein convertases
WO2016144702A1 (en) 2015-03-06 2016-09-15 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY147019A (en) 2002-03-13 2012-10-15 Biogen Idec Inc Anti-alpha v beta 6 antibodies
DK2316831T3 (da) 2002-11-21 2013-06-10 Novartis Ag 2-(Morpholin-4-yl)pyrimidiner som phosphotidylinositol (PI)-3-kinaseinhibitorer samt deres anvendelse ved behandling af cancer
WO2005047268A2 (en) 2003-11-10 2005-05-26 X-Ceptor Therapeutics, Inc. Substituted pyrimidine compositions and methods of use
WO2006031852A1 (en) * 2004-09-13 2006-03-23 Amgen Inc. Vanilloid receptor ligands and their use in treatments
CA2687024A1 (en) 2007-05-09 2009-02-19 Burnham Institute For Medical Research Targeting host proteinases as a therapeutic strategy against viral and bacterial pathogens
KR101247840B1 (ko) * 2008-02-22 2013-03-26 에프. 호프만-라 로슈 아게 아밀로이드 베타 조절제
HRP20171587T1 (hr) 2010-10-18 2017-12-01 Cerenis Therapeutics Holding Sa Spojevi, pripravci i postupci pogodni za mobilizaciju kolesterola
US20150051138A1 (en) 2012-03-16 2015-02-19 Sanford-Burnham Medical Research Institute Inhibitors of furin and other pro-protein convertases
EP2884982B1 (en) 2012-08-20 2017-09-20 Merck Sharp & Dohme Corp. SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
US10150742B2 (en) 2013-03-15 2018-12-11 President And Fellows Of Harvard College Substituted heterocyclic compounds for treating or preventing viral infections
CN107441094B (zh) 2017-08-08 2020-05-22 南方医科大学 尼罗替尼作为治疗登革病毒感染的药物及其制药用途
SG11202010914YA (en) 2018-05-11 2020-12-30 Glaxosmithkline Ip Dev Ltd Furin inhibitors
JP2023503852A (ja) 2019-11-12 2023-02-01 ビーピー アセット ヴイ,インコーポレーテッド 感染症を処置するための低分子フーリン阻害剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007046781A1 (en) 2004-07-23 2007-04-26 Smith, Judith Furin inhibitors
WO2013138665A1 (en) 2012-03-16 2013-09-19 Sanford-Burnham Medical Research Institute Inhibitors of furin and other pro-protein convertases
WO2016144702A1 (en) 2015-03-06 2016-09-15 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof

Also Published As

Publication number Publication date
SG11202010914YA (en) 2020-12-30
IL302997B1 (en) 2024-04-01
CN112384509B (zh) 2024-04-30
CN112384509A (zh) 2021-02-19
IL302997A (en) 2023-07-01
MX2020012034A (es) 2021-04-12
JP7350061B2 (ja) 2023-10-02
EP3790871C0 (en) 2024-01-24
IL278642B2 (en) 2023-10-01
US20220315556A1 (en) 2022-10-06
IL278642A (cg-RX-API-DMAC7.html) 2020-12-31
EP3790871B1 (en) 2024-01-24
AU2019267166B2 (en) 2023-06-15
EP3790871A1 (en) 2021-03-17
AU2019267166A1 (en) 2020-11-26
KR20210021298A (ko) 2021-02-25
WO2019215341A1 (en) 2019-11-14
JP2021523941A (ja) 2021-09-09
US11773078B2 (en) 2023-10-03
CA3099863A1 (en) 2019-11-14
BR112020022961A2 (pt) 2021-02-17
IL278642B1 (en) 2023-06-01
AU2019267166C1 (en) 2023-11-30
IL302997B2 (en) 2024-08-01

Similar Documents

Publication Publication Date Title
US11773078B2 (en) Furin inhibitors
US20250206732A1 (en) Compounds and methods for the targeted degradation of kras
EP3429994B1 (en) 2-cyanoisoindoline derivatives for treating cancer
JP6976953B2 (ja) Rock阻害剤としてのスピロヘプタンサリチルアミドおよび関連性化合物
JP7035055B2 (ja) N-(ピリジン-2-イル)ピリジン-スルホンアミド誘導体および疾患の処置におけるそれらの使用
EP3041842B1 (en) Spirocyclic compounds as tryptophan hydroxylase inhibitors
CN104379574B (zh) 用于抑制abl1、abl2和bcr‑abl1的活性的苯甲酰胺衍生物
JP2018535960A (ja) Acinetobacter baumanniiに対するペプチド大環状分子
KR20210111252A (ko) Irak 분해제 및 이의 용도
CN114144230B (zh) 作为eed和prc2调节剂的大环唑并吡啶衍生物
EP4182308B1 (en) Pyridazinyl amino derivatives as alk5 inhibitors
WO2017024180A1 (en) Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
TW201103929A (en) Heterocyclic urea derivatives and methods of use thereof
WO2014012614A1 (en) Fused triazole derivatives as gamma secretase modulators
JP2022548381A (ja) 置換ベンゾイミダゾールカルボキサミドおよび医学的障害の治療におけるこれらの使用
WO2017006295A1 (en) Hydroxy formamide derivatives and their use
KR20220104744A (ko) 감염성 질환을 치료하기 위한 소분자 푸린 억제제
RU2799824C2 (ru) Ингибиторы фурина
HK40047035B (en) Furin inhibitors
HK40047035A (en) Furin inhibitors
IL303227B2 (en) Combined pumped storage power plant - desalination plant on the beach (ocean), or river, or lake
US20230365531A1 (en) Inhibitors of human respiratory syncytial virus and metapneumo virus
WO2021097002A1 (en) Use of pyridyloxypyrimidines for treating infectious diseases
HK40011732B (en) Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors
HK40011732A (en) Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20201208

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220510

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240822

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250403

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250617

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250618

End annual number: 3

Start annual number: 1

PG1601 Publication of registration